Hurdles for Phage Therapy (PT) to Become a Reality (Record no. 20137)

MARC details
000 -LEADER
fixed length control field 02392nam a2200121Ia 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 220616s9999||||xx |||||||||||||| ||und||
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Brüssow, Harald
245 #0 - TITLE STATEMENT
Title Hurdles for Phage Therapy (PT) to Become a Reality
546 ## - LANGUAGE NOTE
Language note English[eng]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element alginate||abortive infection||n/a||bacterial resistance||bacteriophages||ATMP||MALDI-MS||adaptation||Bacteriophage||horizontal gene transfer||adaptive immunity||co-evolution||Listeria ivanovii||personalised medicines||pH stability||phage-human host interaction||vB_SauM-fRuSau02||antimicrobial resistance||phagodisinfection||biofilm||capsule depolymerase||animal model||phage cocktails||Enterococcus||cases report||zoonosis||resistance||magistral formula||experimental therapy||Belgium||phage therapy||E. faecalis||nontraditional antibacterial||industrial phage application||Democratic Republic of the Congo||OrthoMCL||Germany||high-throughput sequencing||antimicrobial||infection||antibiotic therapy||Kayvirus||phages||Twortlikevirus||bacterial disease||human host||Pseudomonas aeruginosa||phage||multidrug-resistant bacteria||bacterial infection||Salmonella Typhi||rhamnopolysaccharide||compassionate use||crop production||compounding pharmacy||antimicrobial resistance (AMR)||best practices||bacteriophage efficacy||phage sensitivity||antibiotic-resistance||antibiotic||lysins||PTMP||Escherichia coli||typhoid fever||patent landscape||phage preparation||innate immunity||anti-phage antibodies||immunology||Staphylococcus aureus||global health||clinical trial||adsorption||Brussels||phage-resistance||Galleria mellonella||science communication||history of science||virus–host interactions||foodborne illness||prophage||resistance management||biofilms||IND||immunomodulation||frequency of resistance||capsule||gastrointestinal tract||phage-host interactions||disinfection||production||bacteriophage therapy||bacteriophage||Staphylococcus||magistral preparation||extended-spectrum beta lactamases (ESBL)||Viral proteins||antibiotic resistance||genomics||phage biocontrol||therapy||target selection||viral genomes||evolution||pharmaceutical paradigm shift||personalized medicine||pharmaceutical legislation||food safety||regulation||virulence||developing countries||infectious disease||regulatory framework||sustainable agriculture||Klebsiella pneumoniae
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://mdpi.com/books/pdfview/book/1504">https://mdpi.com/books/pdfview/book/1504</a>
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type E-Books
Holdings
Withdrawn status Lost status Damaged status Not for loan Home library Current library Date acquired Total Checkouts Date last seen Price effective from Koha item type
        Kerala University of Digital Sciences, Innovation and Technology Knowledge Centre Kerala University of Digital Sciences, Innovation and Technology Knowledge Centre 16/06/2022   16/06/2022 16/06/2022 E-Books